To further study their therapeutic potential in ALK+, LBCL, a CTLC-ALK-positive LBCL cell line (LM1) was established as a preclinical model to study the role of CLTC- ALK activity in DLBCL lymphomagenesis. The gene discussed is ALK; the disease is diffuse large B-cell lymphoma.